AstraZeneca's IL-33-targeting antibody tozorakimab has made the grade in two phase 3 chronic obstructive pulmonary disease (COPD) trials, raising the prospects of a class that has recorded some ...
AstraZeneca’s chronic obstructive pulmonary disease (COPD) candidate has hit the mark in a pair of phase 3 trials, delivering broad efficacy with a mechanism that yielded mixed data for Roche and ...
Clinical benefits of the interleukin-33 inhibitor were observed in a broad population, including both former and current smokers, regardless of eosinophil levels. Topline results were announced from ...
Ein Pferd wirkt plötzlich ruhiger, frisst schlechter, aus der Nase läuft etwas Sekret. Harmlos? Oft nicht. Kurz darauf wird es ernst: Hohes Fieber, geschwollene Lymphknoten und eitriger Ausfluss ...
43 Prozent der Pferde haben Medienberichten zufolge einmal im Leben einen Sehnenschaden. Das macht ihn zur Top-Verletzung bei den Tieren. Für die Besitzer der verletzten Pferde ist die Diagnose oft ...
Please provide your email address to receive an email when new articles are posted on . Smoking abstinence during week 9 to week 12 among adults with COPD was 19.1% with 12-cytisinicline vs. 4.3% with ...
Please provide your email address to receive an email when new articles are posted on . Patients receiving roflumilast vs. azithromycin had a reduced risk for COPD exacerbations at 1 year but an ...
Chronic obstructive pulmonary disease, or COPD, is the fourth leading cause of death worldwide, responsible for 3.5 million deaths in 2021, according to the World Health Organization. It’s a common ...
Researchers have found a promising treatment breakthrough for chronic obstructive pulmonary disease (COPD) that avoids many of the drawbacks of current drugs, and it has come from an unexpected place.
The path to market for Roche’s astegolimab became more uncertain after the investigational antibody failed to significantly lower disease exacerbation rates versus placebo in patients with chronic ...
Scientists have discovered that people with COPD have lung cells that contain over three times as much soot-like carbon as those of smokers without the disease. These overloaded cells are larger and ...
May 23, 2025 -- The FDA has approved the asthma drug Nucala for adults with chronic obstructive pulmonary disease (COPD). It is the second biologic therapy approved for the condition, following the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results